SCHEMBL25075130

SCHEMBL25075130

CC(C)C1CCN(C(=O)CN2CC[C@@H](C(C)C)C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 1/20 0.43
PKM P14618 1/20 0.40
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 1/20 0.39
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 1/20 0.36
CPN1 P15169 1/20 0.36
CPB2 Q96IY4 1/20 0.36
DPP4 P27487 5/20 0.35
DPP8 Q6V1X1 2/20 0.35
DPP9 Q86TI2 2/20 0.35
DPP7 Q9UHL4 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TMEM97 Q5BJF2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25075124 1.00 BIRC2 (0.43) BIRC2PKMGAAKDM4ELMNA
SCHEMBL26494139 1.00 BIRC2 (0.43) BIRC2PKMGAAKDM4ELMNA
SCHEMBL25075102 0.92 LMNA (0.43) BIRC2PKMGAAKDM4ELMNA
SCHEMBL24330246 0.91 GAA (0.47) BIRC2PKMGAAKDM4ELMNA
SCHEMBL26494147 0.88 HRH3 (0.40) BIRC2PKMGAAKDM4ELMNA
SCHEMBL25075308 0.88 HRH3 (0.40) BIRC2PKMGAAKDM4ELMNA
SCHEMBL26494352 0.88 HRH3 (0.40) BIRC2PKMGAAKDM4ELMNA
SCHEMBL25075313 0.85 BIRC2 (0.38) BIRC2PKMGAAKDM4ELMNA
SCHEMBL25075104 0.85 BIRC2 (0.38) BIRC2PKMGAAKDM4ELMNA
SCHEMBL25075133 0.85 BIRC2 (0.38) BIRC2PKMGAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN BIRC2 360/4885PKM 3752/4885GAA 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.